Business Context and Reporting Period
Company: TriSalus Life Sciences, Inc. (TLSI)
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2026
Reporting Period: Preliminary unaudited results for the fourth quarter and full year ended December 31, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The 8-K serves as a notification that these preliminary results and 2026 revenue guidance were announced via a press release (Exhibit 99.1), which is incorporated by reference but not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Material Changes
No specific material changes or comparative financial data are detailed within the body of this 8-K filing. The document solely references the issuance of the press release containing the operational results.
Guidance, Outlook, and Risks
- Guidance: The Company issued 2026 revenue guidance as part of the January 12, 2026 press release.
- Management Commentary: Specific commentary is contained in the attached press release (Exhibit 99.1) and is not reproduced in the 8-K text.
- Risks and Contingencies: No specific risks or contingencies are disclosed in this filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated January 12, 2026) for actual Q4 and full-year 2025 financial figures.
- Verify the specific 2026 revenue guidance numbers provided in the press release.
- Confirm the status of the Warrants (TLSIW) with an exercise price of $11.50 per share listed on the Nasdaq Global Market.
- Note that the financial data in the press release is preliminary and unaudited.